Skip to content

Swiss VISCOsupplementation Trial 1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN51421587
Enrollment
600
Registered
2004-07-12
Start date
2002-05-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis (OA) of the knee Musculoskeletal Diseases Osteoarthritis of the knee

Interventions

Patients will be allocated to one of three different preparations, a cross-linked formulation (Synvisc®) and non-cross-linked preparations of different origin (Orthovisc® and Ostenil®). Patients will

Sponsors

Swiss Federal Office of Social Insurance (OFAS) (Switzerland)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Men and non-pregnant women with radiologically confirmed symptomatic OA of the knee for at least 6 months 2. Pain on most days for the previous 3 months 3. Fulfil American College of Rheumatology (ACR) clinical criteria for OA of the knee: 3.1. Have an ACR functional class rating of II to IV 3.2. Failed to respond sufficiently 3.3. Intolerant to conservative treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities osteoarthritis index (WOMAC) pain sub-scores.

Secondary

MeasureTime frame
Cost-utility based on health related quality of life measured by EuroQoL and self-reported healthcare utilisation for osteoarthritis

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026